2014 Press Releases

2014 Press Releases
Home / 2014 Press Releases

2014 Press Releases

Sep-29-2014

Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executive Officer

CARMIEL, Israel, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that its Board of Directors has appointed Mr. Moshe Manor as its new President and Chief Executive Officer. Mr. Manor will assume office on November 2, 2014, when Dr. Aviezer will retire. Mr. Shlomo Yanai, Chairman of the Company's Board of Directors, said: "I am delighted that Moshe will be joining us as Chief Executive Officer. He brings extensive knowledge and vast ... 
Sep-04-2014

Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

CARMIEL, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 1:15 PM, Eastern Time. The conference will be held at the New York Palace Hotel in New York City on September 8-10, 2014. A live webcast of the presentation will be available at www.protalix.com ... 
Aug-28-2014

Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs

Conference Call to be Held on Wednesday, September 3, 2014 at 8:30am ET CARMIEL, Israel, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it will host a conference call on Wednesday, September 3, 2014 at 8:30am ET to discuss the recent approval of ELELYSO for pediatric patients as jointly announced with Pfizer on August 28, 2014. In addition, the Company's management will also provide an update on the additional ongoing clinical pr... 
Jul-24-2014

Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors

CARMIEL, Israel, July 24, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of Directors, effective on July 24, 2014. Mr. Zeev Bronfeld, the interim Chairman of the Board, will remain a member of the Board of Directors. "The Board of Protalix and myself are pleased to have Mr. Yanai join our Board as Chairman," stated Mr. Bronfeld.  "He brings extensive knowledge and vast e... 
Jun-27-2014

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 27, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSOTM (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease. "This latest data from the long-term switch over ... 
Jun-23-2014

Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel. Professor Ari Zimran, M.D., Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, is scheduled to deli... 
Jun-18-2014

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease

CARMIEL, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first Gaucher patient has been enrolled in the Company's phase IIa clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112), for the treatment of Gaucher disease. Oral GCD is the Company's proprietary plant cell expressed form of an active glycosylated glucocerebrosidase enzyme (GCD) that is naturally encapsulated within carrot cells and administered... 
Jun-13-2014

Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year

Board of Directors Initiates Succession Process; Dr. Aviezer Remains President and Chief Executive Officer Until His Successor is Named CARMIEL, Israel, June 13, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today, that David Aviezer, Ph.D., has decided to retire after almost 12 years from his role as the Company's President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor.  In the mea... 
May-30-2014

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Health Canada has granted regulatory approval to ELELYSO™ (taliglucerase alfa for injection) for the long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO may also be used for the hematological manifestations in pediatric patients with a confirmed diagnosis of Type 3 Gaucher disease.  EL... 
May-28-2014

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

CARMIEL, Israel, May 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that senior management will present at the Jefferies 2014 Global Healthcare Conference and the Wells Fargo Securities Research & Economics 2014 Healthcare Conference. Details regarding the conferences are as follows: Jefferies 2014 Global Healthcare Conference Monday, June 2, 2014 at 4:00 PM ET The Grand Hyatt, New Y... 
May-22-2014

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval to ELELYSO™ (taliglucerase alfa) for long-term enzyme replacement therapy for both adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia. ELELYSO will be mar... 
May-07-2014

Protalix BioTherapeutics to Present at the Oppenheimer 15th Annual Israeli Conference and the MIXiii Israel Innovation Conference, Biomed

CARMIEL, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 15th Annual Israeli Conference and the MIXiii Israel Innovation Conference, Biomed. Details regarding the conferences are as follows: Oppenheimer 15th Annual Israeli Conference Sunday, May 11, 2014 at 10:15 AM IDT ... 
Apr-23-2014

Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 Meeting

CARMIEL, Israel, April 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for presentation at the Digestive Disease Week (DDW) Annual Meeting being held May 3-6 in Chicago, Illinois. Yaron Ilan, M.D., Professor of Medicine of the Gastroenterology and Liver Units and Director of the Department of Medicine at Hebrew University-Hadassah Medical Center in Jerusalem, Israel, will prese... 
Feb-12-2014

Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014

CARMIEL, Israel, Feb. 12, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor Ari Zimran at the 10th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2014 being held February 10-13 in San Diego, CA. Oral GCD is the Company's orally-delivered proprietary formulation of the plant cell-expressed enzyme, glucocerebro... 
Feb-06-2014

Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property

CARMIEL, Israel, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Brazilian National Institute of Industrial Property (INPI) has approved the Company's previously-announced supply and technology transfer agreement with Fundação Oswaldo Cruz (commonly referred to as Fiocruz), an arm of the Brazilian Ministry of Health for UPLYSO™ (alfataliglicerase). The Company announced the execution of the supply and technology transfer agreeme... 
Jan-23-2014

Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada

CARMIEL, Israel, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Health Canada has completed a successful on-site evaluation of the Company's manufacturing facility in Carmiel, Israel, as part of its ongoing review of the new drug submission (NDS) for taliglucerase alfa for the treatment of Gaucher disease.  The purpose of the on-site evaluation was to verify the facility's compliance with certain Canadian food and drug regulations... 
Jan-13-2014

Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook

Dr. Aviezer to Present at the 32nd Annual J.P. Morgan Healthcare Conference CARMIEL, Israel, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will discuss the Company's corporate objectives and key milestones in a presentation at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. Dr. Aviezer's presentation... 
Jan-07-2014

Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

CARMIEL, Israel, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 13-16, 2014.  A live webcast of the presentation will be available at www.p...